Monday, October 26, 2026 · Daily editionET --:--:--

Looking for volunteers

Synapse 3D With Intravascular Indocyanine Green

NCT03953144 · St. Joseph's Healthcare Hamilton · Updated 2 Feb 2026

What is being tested
Synapse 3D Lung Modelling; IC-Green (ICG)
For
Non-small Cell Lung Cancer; Primary Neoplasm
Kind of study
Tests a treatment or device on volunteers. Phase 1 and Phase 2.
Who can join
Ages 18 years and older. About 32 people. The full rules are on the registry page.
Where
Canada
When
Starts or started 1 Dec 2022, ends 31 Dec 2026. Registered 16 May 2019.
Results
None posted yet.

In the researchers' words

With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly. As such, there is a need to develop new surgical techniques to facilitate minimally invasive pulmonary segmentectomy, as segmentectomy may provide a number of significant advantages over lobectomy for patients presenting with early-stage lung cancer, or for patients unable to undergo a full lobectomy due to existing comorbidities. This study will provide the first case series using preoperative 3D anatomical planning (Synapse 3D) added to ICG and NIF-guided robotic segmentectomy to date and will be the first reported use of Synapse 3D-guided targeted pulmonary segmental resection in Canada. As lung cancer is the most frequently fatal cancer in North America, many thousands of patients will be able to benefit from this operation every year.
ClinicalTrials.gov, NCT03953144

Sites

  • St. Josephs Healthcare HamiltonHamilton, Ontario, Canada